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BACKGROUND
The effect of decompressive craniectomy on clinical outcomes in patients with refractory 
traumatic intracranial hypertension remains unclear.
METHODS
From 2004 through 2014, we randomly assigned 408 patients, 10 to 65 years of age, with 
traumatic brain injury and refractory elevated intracranial pressure (>25 mm Hg) to undergo 
decompressive craniectomy or receive ongoing medical care. The primary outcome was the 
rating on the Extended Glasgow Outcome Scale (GOS-E) (an 8-point scale, ranging from 
death to “upper good recovery” [no injury-related problems]) at 6 months. The primary-
outcome measure was analyzed with an ordinal method based on the proportional-odds 
model. If the model was rejected, that would indicate a significant difference in the GOS-E 
distribution, and results would be reported descriptively.
RESULTS
The GOS-E distribution differed between the two groups (P<0.001). The proportional-odds 
assumption was rejected, and therefore results are reported descriptively. At 6 months, the 
GOS-E distributions were as follows: death, 26.9% among 201 patients in the surgical 
group versus 48.9% among 188 patients in the medical group; vegetative state, 8.5% versus 
2.1%; lower severe disability (dependent on others for care), 21.9% versus 14.4%; upper 
severe disability (independent at home), 15.4% versus 8.0%; moderate disability, 23.4% 
versus 19.7%; and good recovery, 4.0% versus 6.9%. At 12 months, the GOS-E distributions 
were as follows: death, 30.4% among 194 surgical patients versus 52.0% among 179 
medical patients; vegetative state, 6.2% versus 1.7%; lower severe disability, 18.0% versus 
14.0%; upper severe disability, 13.4% versus 3.9%; moderate disability, 22.2% versus 20.1%; 
and good recovery, 9.8% versus 8.4%. Surgical patients had fewer hours than medical pa-
tients with intracranial pressure above 25 mm Hg after randomization (median, 5.0 vs. 17.0 
hours; P<0.001) but had a higher rate of adverse events (16.3% vs. 9.2%, P = 0.03).
CONCLUSIONS
At 6 months, decompressive craniectomy in patients with traumatic brain injury and 
refractory intracranial hypertension resulted in lower mortality and higher rates of veg-
etative state, lower severe disability, and upper severe disability than medical care. The 
rates of moderate disability and good recovery were similar in the two groups. (Funded by 
the Medical Research Council and others; RESCUEicp Current Controlled Trials number, 
ISRCTN66202560.)
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A fter traumatic brain injury (TBI), intracranial pressure can be elevated ow-ing to a mass effect from intracranial 
hematomas, contusions, diffuse brain swelling, 
or hydrocephalus.1 Intracranial hypertension can 
lead to brain ischemia by reducing the cerebral 
perfusion pressure.2 Intracranial hypertension 
after TBI is associated with an increased risk of 
death in most studies.3,4 The monitoring of intra-
cranial pressure and the administration of in-
terventions to lower intracranial pressure are 
routinely used in patients with TBI, despite the 
lack of level 1 evidence.5
Decompressive craniectomy is a surgical 
procedure in which a large section of the skull 
is removed and the underlying dura mater is 
opened.6 Primary decompressive craniectomy re-
fers to leaving a large bone flap out after the 
evacuation of an intracranial hematoma in the 
early phase after a TBI.7,8 Cranial reconstruction 
is undertaken a few weeks to months later with 
autologous bone (the removed bone flap is stored 
in the patient’s abdominal wall or a freezer) or 
an implant (titanium or other synthetic material). 
A secondary decompressive craniectomy is used 
as part of tiered therapeutic protocols that are 
frequently used in intensive care units (ICUs) in 
order to control raised intracranial pressure and 
to ensure adequate cerebral perfusion pressure 
after TBI.7,8 For example, in the Decompressive 
Craniectomy (DECRA) trial,9 patients who had 
an intracranial pressure of more than 20 mm Hg 
for more than 15 minutes (continuously or inter-
mittently) within a 1-hour period, despite opti-
mized first-tier interventions, were randomly 
assigned to early bifrontal decompressive crani-
ectomy and standard care or to standard care 
alone. The authors found that decompressive 
craniectomy was associated with more unfavor-
able outcomes than standard care alone. Alter-
natively, craniectomy can be performed as a last-
tier intervention when the intracranial pressure 
remains elevated despite all other measures.10,11 
We conducted the Randomised Evaluation of 
Surgery with Craniectomy for Uncontrollable 
Elevation of Intracranial Pressure (RESCUEicp) 
trial to assess the effectiveness of craniectomy 
as a last-tier intervention in patients with TBI 
and refractory intracranial hypertension.
Me thods
Trial Design and Oversight
In this international, multicenter, parallel-group, 
superiority, randomized trial, we compared last-
tier secondary decompressive craniectomy with 
continued medical management for refractory 
intracranial hypertension after TBI. Ethics ap-
proval in the United Kingdom was obtained in 
2003 from the Cambridgeshire 4 research ethics 
committee (formerly known as the Eastern multi-
center research ethics committee); ethics com-
mittees at all other participating institutions 
also approved the trial.
Because the trial enrolled patients with severe 
TBI, written informed consent was obtained from 
the nearest relative or a person who had been 
designated to give consent on admission of the 
patient. An independent steering committee and 
an independent data monitoring and ethics 
committee reviewed the trial regularly to assess 
conduct, progress, and safety.
The trial protocol, available with the full text 
of this article at NEJM.org, was designed in a 
collaborative fashion by the Divisions of Neuro-
surgery and Anaesthesia at the University of 
Cambridge, collaborating clinicians, and the 
European Brain Injury Consortium. Full details 
of the protocol have been published previously.11 
The investigators vouch for the completeness 
and accuracy of the data and the analyses and 
for the fidelity of this report to the trial protocol 
and the statistical analysis plan.
Participants and Trial Sites
To undergo randomization in the trial, patients 
had to be between 10 and 65 years of age, have 
a TBI with an abnormal computed tomographic 
(CT) scan of the brain, have an intracranial-
pressure monitor already in place, and have 
raised intracranial pressure (>25 mm Hg for 1 to 
12 hours, despite stage 1 and 2 measures, as 
defined below and in Fig. 1). Patients who had 
undergone an immediate operation for evacua-
tion of an intracranial hematoma could be in-
cluded as long as the operation was not a crani-
ectomy (i.e., the bone flap was replaced at the 
end of procedure). Patients with bilateral fixed 
and dilated pupils, bleeding diathesis, or an in-
A Quick Take is 
available at 
NEJM.org 
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jury that was deemed to be unsurvivable were 
excluded. Trial sites were hospitals that provide 
acute neurosciences care for patients with severe 
TBI and that have 24-hour neurosurgical services 
(see the Supplementary Appendix, available at 
NEJM.org).
Interventions and Randomization
Patients were treated in ICUs according to a 
protocol that was aimed at maintaining an intra-
cranial pressure of 25 mm Hg or less by apply-
ing treatments in a stepwise manner (Fig. 1). 
The initial stage (stage 1) included sedation, 
analgesia, and head elevation; neuromuscular 
paralysis was optional. Other targets included a 
cerebral perfusion pressure (the difference be-
tween the mean blood pressure and intracranial 
pressure) of more than 60 mm Hg, normother-
mia, normoglycemia, mild hypocapnia (partial 
pressure of arterial carbon dioxide [PaCO2], 4.5 to 
5.0 kPa [34 to 38 mm Hg]), and adequate oxy-
genation (oxygen saturation, >97%). If the intra-
cranial pressure was not controlled, stage 2 op-
tions included ventriculostomy (if an external 
ventricular drain had not already been inserted 
for intracranial-pressure monitoring), pharmaco-
logic blood-pressure augmentation, osmotherapy, 
moderate hypocapnia (PaCO2, 4.0 to 4.5 kPa 
[30 to 34 mm Hg]), and therapeutic hypothermia 
(not <34°C).
If the intracranial pressure remained above 
25 mm Hg for 1 to 12 hours despite these mea-
sures, then at stage 3 of the protocol, patients 
were randomly assigned to undergo decompres-
sive craniectomy with medical therapy or to re-
ceive continued medical therapy with the option 
of adding barbiturates to reduce the intracranial 
pressure. Patients underwent randomization, in 
a 1:1 ratio, with the use of permuted blocks of 
random sizes and with stratification according 
to trial site. To ensure concealment, the block 
sizes were not disclosed. Participants underwent 
randomization with the use of a central tele-
phone randomization service. Concealment of the 
trial-group assignments was ensured, because 
the service did not release the randomization 
code until the patient had reached stage 3 of the 
protocol.
The surgical treatment was either large uni-
lateral frontotemporoparietal craniectomy (hemi-
craniectomy), which was recommended for pa-
tients with unilateral hemispheric swelling, or 
bifrontal craniectomy, which was recommended 
for patients with diffuse brain swelling that 
affected both hemispheres on imaging studies. 
The exact type of craniectomy was left to the 
discretion of the surgeons. Details of the recom-
mended surgical technique are provided in the 
protocol. In addition, it was recommended that 
Figure 1. Stages of Therapeutic Management.
Agreement for participation was obtained from the nearest relative or a per-
son who had been designated to give consent preemptively on admission of 
the patient in order to avoid delays in treatment. Randomization was per-
formed after stage 2 if the intracranial pressure was more than 25 mm Hg 
for 1 to 12 hours. The protocol stages 1 and 2 reflected the therapeutic 
protocols that were followed in the participating units.
Intracranial pressure >25 mm Hg
for 1–12 hr
Continue stage 1 treatments
Barbiturates not permitted
Optional treatments that can 
be added
Ventriculostomy
Inotropes
Mannitol
Hypertonic saline
Loop diuretics
Hypothermia
Intracranial pressure >25 mm Hg
Initial treatment measures
Head elevation
Ventilation
Sedation
Analgesia
Paralysis (optional)
Monitoring
Central venous pressure
Arterial blood pressure
Intracranial pressure
Surgical group
Decompressive craniectomy
Continue stage 1 and 2 treatments
Medical group
Continue stage 1 and 2 treatments
Barbiturates permitted
Stage 1
Stage 3
Stage 2
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surgery should be performed no later than 4 to 
6 hours after randomization.
Patients who were assigned to receive medical 
treatment alone could undergo a decompressive 
craniectomy later in case their condition deterio-
rated further, at the discretion of treating clini-
cians. Similarly, patients who were assigned to 
undergo decompressive craniectomy could have 
barbiturate infusion in case of further deteriora-
tion of their condition.
Outcomes
The primary-outcome measure was assessed with 
the use of the Extended Glasgow Outcome Scale 
(GOS-E) at 6 months after randomization.12 The 
GOS-E is a global outcome scale assessing func-
tional independence, work, social and leisure 
activities, and personal relationships. Its eight 
outcome categories are as follows: death, vegeta-
tive state (unable to obey commands), lower se-
vere disability (dependent on others for care), 
upper severe disability (independent at home), 
lower moderate disability (independent at home 
and outside the home but with some physical or 
mental disability), upper moderate disability 
(independent at home and outside the home but 
with some physical or mental disability, with 
less disruption than lower moderate disability), 
lower good recovery (able to resume normal ac-
tivities with some injury-related problems), and 
upper good recovery (no problems). Details are 
provided in the Supplementary Appendix.
In the United Kingdom, the trial office in 
Cambridge mailed the GOS-E questionnaires 
to surviving participants. If no response was 
received, a trial team member contacted the 
patient or a caregiver by telephone to complete 
the questionnaire. At international sites, local 
staff were responsible for the above processes. 
Two trial team investigators, who were unaware 
of the trial-group assignments, centrally adjudi-
cated outcomes on the basis of the GOS-E ques-
tionnaires independently of each other accord-
ing to a standardized approach.13 Disagreements 
were resolved by consensus between them or 
with the consultation of a third trial team inves-
tigator who was also unaware of the trial-group 
assignments.
The secondary outcomes were the following: 
GOS-E results at 12 and 24 months after ran-
domization; mortality at 6, 12, and 24 months 
after randomization; quality of life at 6, 12, and 
24 months after randomization; Glasgow Coma 
Scale (GCS) score at discharge from the neuro-
sciences hospital; assessment of intracranial-
pressure control; time in the ICU; time to dis-
charge from the neurosciences hospital; and 
economic evaluation. Quality of life was as-
sessed with the 36-item Short-Form Health Sur-
vey in adults and the 10-item Short-Form Health 
Survey in children. Assessment of intracranial-
pressure control included the mean intracranial 
pressure in the period after randomization, the 
number of hours with the intracranial pressure 
above 25 mm Hg in the period after randomiza-
tion, the intracranial hypertension index 20 (the 
number of end-hourly measures of intracranial 
pressure of >20 mm Hg divided by the total 
number of measurements, multiplied by 100), 
the intracranial hypertension index 25 (the num-
ber of end-hourly measures of intracranial pres-
sure of >25 mm Hg divided by the total number 
of measurements, multiplied by 100), and the 
cerebral hypoperfusion index (the number of 
end-hourly measures of cerebral perfusion pres-
sure of <60 mm Hg divided by the total number 
of measurements, multiplied by 100). Data on 
complications and serious adverse events were 
also collected.
Statistical Analysis
We calculated that a target sample of 400 pa-
tients would allow us to detect a treatment effect 
of 15 percentage points between the two groups 
(difference in favorable-outcome rate of 45% vs. 
60%; see the definition of favorable outcome 
later in this section) with 80% power at the 5% 
significance level (two-sided), allowing for a loss 
to follow-up of up to 15%.11 The analysis was 
performed according to a statistical analysis 
plan, which was agreed on without reference to 
the unblinded data (see the protocol).14
Outcomes were reported in the intention-to-
treat population, which was modified to exclude 
patients who were lost to follow-up or who with-
drew consent. Missing outcome data were not 
imputed. As prespecified in the statistical analy-
sis plan, a sensitivity analysis was performed for 
the primary-outcome measure in the per-proto-
col population. The per-protocol population was 
defined as the patients in the intention-to-treat 
population who did not have a severe breach of 
protocol.
The primary-outcome measure was analyzed 
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with an ordinal analysis method that was based 
on the proportional-odds model.15 The goodness 
of fit of the unadjusted proportional-odds models 
was tested with the use of a likelihood-ratio test. 
The rejection of the proportional-odds model at 
the 5% significance level indicated a difference 
in the GOS-E distribution between the two ran-
domized groups. In this situation, the presenta-
tion of the results was prespecified to describe 
the difference in outcomes between the groups, 
and the groups were compared formally with the 
use of an unordered chi-square test. For the pri-
mary analysis, the GOS-E categories of upper 
good recovery and lower good recovery were 
pooled, since a blinded review of the distribu-
tion of GOS-E ratings revealed that there were 
too few patients in these categories for them to 
be analyzed separately.
In a prespecified sensitivity analysis, we com-
pared the proportion of patients who had an 
outcome of upper severe disability or better on 
the GOS-E scale (“favorable outcome”) between 
the randomized groups, using a chi-square test. 
Conventionally, the GOS-E scale is dichotomized 
so that upper severe disability is categorized as 
being an unfavorable outcome, together with 
vegetative state and lower severe disability. Pa-
tients who are in the category of upper severe 
disability are largely independent around their 
homes but need assistance with traveling or 
shopping, whereas patients who are in the cate-
gory of lower severe disability live in a super-
vised facility (care facility) or, if at home, need 
assistance most of the time. In view of the antici-
pated high proportion of poor outcomes in this 
trial population, it was agreed a priori by the trial 
team and the steering committee that the upper-
severe-disability category would be included in 
the definition of favorable outcome. A similar 
approach has been followed in some trials of 
craniectomy for middle-cerebral-artery infarction, 
in which moderately severe disability (modified 
Rankin scale score, 4 [unable to walk without 
assistance and unable to attend to own bodily 
needs without assistance]) was categorized as a 
favorable outcome, although most stroke trials 
conventionally categorize it as unfavorable.16,17
Prespecified exploratory analyses examined 
the effect of covariate adjustment (age, GCS mo-
tor score, pupillary reactivity, and the Marshall 
grade of the last available prerandomization CT 
of the brain) on the analyses described above. 
The duration of ICU stay was analyzed with the 
use of Kaplan–Meier estimates and log-rank tests. 
The time to discharge from the neurosciences 
hospital and the GCS score at discharge from 
the neurosciences hospital were not analyzed 
because the data were not collected. Instead, the 
GCS score at the time of discharge from the ICU 
was available and was analyzed with the use of 
the same ordinal method as described above for 
the GOS-E. All other analyses of categorical data 
were based on chi-square tests, and analyses 
of continuous variables were based on Mann–
Whitney U tests. The GOS-E ratings at 24 months, 
quality-of-life data, and the planned economic 
evaluation have not yet been analyzed.
R esult s
Recruitment and Characteristics  
of the Patients
The first patient was enrolled in January 2004, 
and the trial was closed to recruitment in March 
2014, when the intended sample size was reached. 
A total of 2008 patients were assessed for trial 
eligibility, and 409 patients at 52 centers in 20 
countries underwent randomization; of these 
patients, 291 (71.1%) were recruited in the United 
Kingdom. One patient underwent randomization 
twice in error, therefore leaving 408 patients. Of 
these patients, 206 were assigned to the surgical 
group and 202 to the medical group (see the 
Supplementary Appendix). Five patients were 
excluded from the analysis owing to withdrawal 
of consent, and 5 were excluded owing to a lack 
of valid informed consent, leaving 202 patients 
in the surgical group and 196 in the medical 
group. Of the 398 remaining patients, 389 were 
evaluated for the primary outcome (201 patients 
in the surgical group and 188 in the medical 
group), and 373 were evaluated at 12 months 
(194 in the surgical group, and 179 in the medi-
cal group). The characteristics of the two groups 
were similar at baseline, except that fewer pa-
tients in the surgery group than in the medical 
group had a history of drug or alcohol abuse 
(Table 1).
Interventions
Similar numbers of patients in the two groups 
received stage 1 and stage 2 treatments that had 
been designated as optional (Table 2). No signifi-
cant between-group differences were observed 
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in the rate of craniotomies performed before 
randomization or in the type of evacuated hema-
tomas.
In the surgical group, 92.6% of the patients 
underwent decompressive craniectomy (Table 2). 
The median time from randomization to crani-
ectomy was 2.2 hours.
In the medical group, 87.2% of the patients 
received a barbiturate infusion (Table 2). The 
median time from randomization to barbiturate 
infusion was 1.5 hours. The median duration of 
barbiturate therapy was 53 hours. Decompres-
sive craniectomy was performed in 37.2% of the 
patients in the medical group. (See Tables S3 
and S8 in the Supplementary Appendix.)
Outcomes
Primary Outcome
In a modified intention-to-treat analysis, the 
prespecified ordinal regression showed evidence 
of a difference in the 6-month GOS-E distribu-
tion between the two groups (χ2 = 7.72, 1 df, 
P = 0.005). However, the goodness-of-fit test re-
jected the proportional-odds assumption that un-
derlies the ordinal regression analysis (χ2 = 22.86, 
5 df, P<0.001). Therefore, the common odds ratio 
could not be used to describe the direction and 
magnitude of the treatment effect that was ob-
served with the ordinal regression. Hence, as 
prespecified, the remaining analyses aimed 
to describe the way in which the distribution of 
GOS-E ratings differed between the two random-
ized groups. The unordered test comparing the 
distribution of the GOS-E ratings over the two 
groups yielded a χ2 of 30.69 (7 df, P<0.001).
At 6 months after randomization, the GOS-E 
distributions were as follows: death, 26.9% 
among 201 patients in the surgical group and 
48.9% among 188 patients in the medical group; 
vegetative state, 8.5% versus 2.1%; lower severe 
disability (dependent on others for care), 21.9% 
versus 14.4%; upper severe disability (indepen-
dent at home), 15.4% versus 8.0%; moderate 
disability, 23.4% versus 19.7%; and good recovery, 
Characteristic
Surgical Group 
(N = 202)
Medical Group 
(N = 196)
Age — yr 32.3±13.2 34.8±13.7
Male sex — no./total no. (%) 165/202 (81.7) 156/195 (80.0)
GCS motor score at first hospital — no./total no. (%)†
1 or 2 96/181 (53.0) 85/170 (50.0)
3–6 85/181 (47.0) 85/170 (50.0)
Pupillary abnormality — no. (%)‡ 59 (29.2) 57 (29.1)
Hypotension — no. (%)§ 40 (19.8) 42 (21.4)
Hypoxemia — no. (%)¶ 49 (24.3) 52 (26.5)
History of drug or alcohol abuse — no. (%) 50 (24.8) 69 (35.2)
Extracranial injury — no. (%) 75 (37.1) 83 (42.3)
Injury classification on basis of CT imaging — no./total no. (%)‖
Diffuse injury 161/198 (81.3) 141/186 (75.8)
Mass lesion 37/198 (18.7) 45/186 (24.2)
*  Plus–minus values are means ±SD. There were no significant between-group differences in these baseline characteris-
tics except for history of drug or alcohol abuse (P = 0.02). Additional baseline data are provided in Tables S1, S2, and 
S4 through S7 in the Supplementary Appendix.
†  A Glasgow Coma Scale (GCS) motor score of 1 indicates that the patient makes no movements to painful stimuli, 2 has 
extension, 3 has abnormal flexion, 4 has normal flexion, 5 localizes to painful stimuli, and 6 obeys commands.
‡  Pupil abnormality was defined as the presence of unreactive pupils or anisocoria.
§  Hypotension was defined as a systolic blood pressure of less than 90 mm Hg.
¶  Hypoxemia was defined as a partial pressure of arterial oxygen of less than 8 kPa (60 mm Hg).
‖  Injury classification was determined on the basis of the Marshall classification of the prerandomization CT image of 
the head (Table S5 in the Supplementary Appendix). If the prerandomization CT image of the head was not available, 
the classification was done on the basis of the Marshall classification of the initial CT of the head, taking into account 
whether a craniotomy for evacuation of a mass lesion had occurred before randomization.
Table 1. Characteristics of the Patients at Baseline.*
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on November 1, 2016. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 375;12 nejm.org September 22, 2016 1125
Decompressive Cr aniectomy for Intr acr anial Hypertension
4.0% versus 6.9% (Table 3 and Fig. 2). In a pre-
specified sensitivity analysis, favorable outcomes 
(prespecified as upper severe disability or better 
on the GOS-E) occurred in 42.8% of the patients 
in the surgical group and in 34.6% of those in 
the medical group (P = 0.12) (Fig. S1 in the Sup-
plementary Appendix). Using the absolute differ-
ences presented in Table 3, we estimated that for 
every 100 patients treated with surgical rather 
than medical intent, there were 22 more survi-
vors; of these 22 patients, 6 were in a vegetative 
state (27%), 8 were categorized as having lower 
severe disability (36%), and 8 were categorized 
as having upper severe disability or better (36%).
Secondary Outcomes
At 12 months after randomization, the GOS-E 
distributions were as follows: death, 30.4% 
among 194 patients in the surgical group versus 
52.0% among 179 patients in the medical group; 
vegetative state, 6.2% versus 1.7%; lower severe 
disability, 18.0% versus 14.0%; upper severe dis-
ability, 13.4% versus 3.9%; moderate disability, 
22.2% versus 20.1%; and good recovery, 9.8% 
versus 8.4% (Table 3 and Fig. 2). In a prespeci-
fied sensitivity analysis, favorable outcomes (up-
per severe disability or better) occurred in 45.4% 
of the patients in the surgical group, as com-
pared with 32.4% of those in the medical group 
(P = 0.01). Using the absolute differences pre-
sented in Table 3, we estimated that for every 
100 patients treated with surgical rather than 
medical intent, there were 22 more survivors; of 
these 22 patients, 5 were in a vegetative state 
(23%), 4 were categorized as having lower severe 
disability (18%), and 13 were categorized as hav-
ing upper severe disability or better (59%). Ad-
justment of the GOS-E ratings at 6 months and 
at 12 months for the prespecified covariates did 
not alter the results. (Details are provided in Fig. 
S2 and Tables S12 and S16 in the Supplementary 
Appendix.)
Similar to the GOS-E results at 6 months, the 
goodness-of-fit test rejected the proportional-
odds assumption in analyses of the GCS scores 
(χ2 = 10.79, 3 df, P = 0.01); descriptive results are 
shown in Table 3. Control of intracranial pres-
sure was better in the surgical group than in the 
medical group, as shown by the significant dif-
ferences in the five relevant prespecified mea-
sures (Table 3). There was no between-group 
difference in the median values of time to dis-
charge (including death) in the ICU. A time-to-
event analysis of length of stay, with follow-up 
Treatment or Intervention
Surgical Group 
(N = 202)
Medical Group 
(N = 196)
Craniotomy for evacuation of hematoma — no. (%) 26 (12.9) 30 (15.3)
Ventriculostomy — no. (%) 34 (16.8) 43 (21.9)
Neuromuscular paralysis — no. (%) 101 (50.0) 103 (52.6)
Pharmacologic blood-pressure augmentation — no. (%) 112 (55.4) 116 (59.2)
Osmotherapy — no. (%) 146 (72.3) 144 (73.5)
Therapeutic hypothermia — no. (%) 47 (23.3) 53 (27.0)
Decompressive craniectomy — no. (%)† 187 (92.6) 73 (37.2)
Bifrontal — no./total no. (%) 109/173 (63.0) NA
Unilateral — no./total no. (%) 64/173 (37.0) NA
Barbiturates — no. (%)‡ 19 (9.4) 171 (87.2)
*  There were no significant between-group differences with respect to therapeutic interventions administered before ran-
domization. Decompressive craniectomy and barbiturates were administered only in the period after randomization. 
NA denotes not applicable.
†  The reasons for not performing decompressive craniectomy were further deterioration of the patient, control of intra-
cranial pressure while waiting for surgery, uncorrected coagulopathy, and massive epistaxis on positioning of the patient. 
The type of decompressive craniectomy was unknown in 14 patients in the surgical group. Information on decompres-
sive craniectomy was only collected in the surgical group.
‡  The median duration of barbiturate therapy in the medical group was 53 hours (interquartile range, 24.5 to 115). Data 
on the duration of therapy were available for 122 patients.
Table 2. Treatments and Interventions.*
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Variable
Surgical Group 
(N = 202)
Medical Group 
(N = 196)
Absolute Difference 
(95% CI)† P Value
percentage points
GOS-E result — no./total no. (%)‡ <0.001
At 6 mo
Death 54/201 (26.9) 92/188 (48.9) −22.1 (−31.5 to −12.7)
Vegetative state 17/201 (8.5)  4/188 (2.1) 6.3 (2.0 to 10.7)
Lower severe disability 44/201 (21.9) 27/188 (14.4) 7.5 (−0.1 to 15.1)
Upper severe disability 31/201 (15.4) 15/188 (8.0) 7.4 (1.1 to 13.8)
Lower moderate disability 20/201 (10.0) 19/188 (10.1) −0.1 (−6.1 to 5.8)
Upper moderate disability 27/201 (13.4) 18/188 (9.6) 3.9 (−2.5 to 10.2)
Lower good recovery 5/201 (2.5)  6/188 (3.2) −0.7 (−4.0 to 2.6)
Upper good recovery 3/201 (1.5)  7/188 (3.7) −2.2 (−5.4 to 1.0)
At 12 mo <0.001
Death 59/194 (30.4) 93/179 (52.0) −21.5 (−31.3 to −11.8)
Vegetative state 12/194 (6.2)  3/179 (1.7) 4.5 (0.6 to 8.4)
Lower severe disability 35/194 (18.0) 25/179 (14.0) 4.1 (−3.3 to 11.5)
Upper severe disability 26/194 (13.4)  7/179 (3.9) 9.5 (3.9 to 15.1)
Lower moderate disability 20/194 (10.3) 14/179 (7.8) 2.5 (−3.3 to 8.3)
Upper moderate disability 23/194 (11.9) 22/179 (12.3) −0.4 (−7.1 to 6.2)
Lower good recovery 14/194 (7.2)  7/179 (3.9) 3.3 (−1.3 to 7.9)
Upper good recovery 5/194 (2.6)  8/179 (4.5) −1.9 (−5.7 to 1.9)
GCS score or death at discharge from ICU — no./total no. (%)§ <0.001
Death 42/185 (22.7) 83/171 (48.5) −25.8 (−35.5 to −16.2)
GCS score
3–5 13/185 (7.0) 11/171 (6.4) 0.6 (−4.6 to 5.8)
6–8 22/185 (11.9) 10/171 (5.8) 6.0 (0.2 to 11.9)
9–12 67/185 (36.2) 37/171 (21.6) 14.6 (5.3 to 23.9)
13–15 41/185 (22.2) 30/171 (17.5) 4.6 (−3.6 to 12.9)
Intracranial-pressure control¶
Median mean intracranial pressure after randomization 
(IQR) — mm Hg
14.5 (1.7–18.0) 17.1 (4.2–21.8) −3.0 (−4.1 to −1.8) <0.001
Median duration of intracranial pressure >25 mm Hg 
after randomization (IQR) — hr
5.0 (0.0–17.0) 17.0 (5.0–35.0) −8.0 (−12.0 to −5.0) <0.001
Median intracranial hypertension index 20 (IQR) 18.1 (9.9–36.7) 31.4 (18.2–54.2) −10.4 (−14.5 to −6.7) <0.001
Median intracranial hypertension index 25 (IQR) 6.6 (3.1–13.6) 11.8 (5.6–27.8) −4.2 (−6.2 to −2.5) <0.001
Median cerebral hypoperfusion index 60 (IQR) 6.8 (3.1–16.6) 11.1 (4.4–24.8) −2.8 (−4.9 to −1.0) 0.002
*  ICU denotes intensive care unit, and IQR interquartile range.
†  Absolute differences between percent values are percentage points and may not sum exactly owing to rounding. For median values, the 
treatment groups were compared with the use of the Mann–Whitney U test and the corresponding confidence interval. The estimated dif-
ference between the median values is not simply the observed difference between the median values.
‡  P values for the comparisons of the Extended Glasgow Outcome Scale (GOS-E) results were calculated by means of unordered chi-square tests. 
The eight outcome categories on the GOS-E are death, vegetative state (unable to obey commands), lower severe disability (dependent on others 
for care), upper severe disability (independent at home), lower moderate disability (independent at home and outside the home but with some 
physical or mental disability), upper moderate disability (independent at home and outside the home but with some physical or mental dis-
ability, with less disruption than lower moderate disability), lower good recovery (able to resume normal activities with some injury-related 
problems), and upper good recovery (no problems). See the Supplementary Appendix for additional descriptions of the outcome categories.
§  The GCS was used for assessing impairment of the level of consciousness. Scores range from 3 to 15, with lower scores indicating greater 
impairment. The P value was calculated by means of an unordered chi-square test.
¶  The mean intracranial pressure after randomization and the duration of intracranial pressure of more than 25 mm Hg after randomization could 
be calculated for 165 patients in the surgical group and for 160 in the medical group. The three indexes could be calculated for 192 patients in 
the surgical group and for 183 in the medical group. The intracranial hypertension index 20 is the number of end-hourly measures of intracranial 
pressure of more than 20 mm Hg divided by the total number of measurements, multiplied by 100. The intracranial hypertension index 25 is the 
number of end-hourly measures of intracranial pressure of more than 25 mm Hg divided by the total number of measurements, multiplied by 
100. The cerebral hypoperfusion index 60 is the number of end-hourly measures of cerebral perfusion pressure of less than 60 mm Hg divided 
by the total number of measurements, multiplied by 100.
Table 3. Analysis of Primary and Secondary Outcomes.*
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data censored at death for patients who died in 
the ICU, showed that the median time to dis-
charge among survivors was 15.0 days in the 
surgical group, as compared with 20.8 days in 
the medical group (P = 0.01). Adverse events were 
reported in 16.3% of the patients in the surgical 
group, as compared with 9.2% of those in the 
medical group (P = 0.03). (Details are provided in 
Tables S9, S10, S17, and S18 in the Supplemen-
tary Appendix.)
Four patients had a severe breach of protocol 
(intracranial pressure not monitored before ran-
domization in one patient in the surgical group, 
age outside the upper cutoff in two [one patient 
in each group], and uncorrected bleeding diathe-
sis in one in the surgical group) and were not 
included in the per-protocol population. The per-
protocol analysis of the GOS-E results at 6 months 
did not alter the findings that were observed in 
the modified intention-to-treat analysis. A post 
hoc sensitivity analysis of the worst-case sce-
nario for mortality at 6 months did not alter the 
results. In a further sensitivity analysis, results 
were explored for six a priori subgroups. (See 
Tables S13, S14, and S15 in the Supplementary 
Appendix.)
Discussion
In this trial involving patients with sustained and 
refractory intracranial hypertension after TBI, the 
GOS-E distributions at 6 months were as follows: 
death, 26.9% in the surgical group and 48.9% in 
the medical group; vegetative state, 8.5% versus 
2.1%; lower severe disability (dependent on others 
for care), 21.9% versus 14.4%; upper severe dis-
ability (independent at home), 15.4% versus 8.0%; 
moderate disability, 23.4% versus 19.7%; and 
good recovery 4.0% versus 6.9%. The rate of an 
outcome of upper severe disability or better was 
42.8% in the surgical group versus 34.6% in the 
medical group.
The treatment protocol of the trial was orga-
nized in three hierarchical stages, with treatment 
intensity increasing at every stage. All stage 2 
interventions, neuromuscular paralysis (stage 1), 
and barbiturate infusion after randomization in 
the medical group were designated as optional 
in view of the lack of level 1 evidence regarding 
their efficacy at the time of trial initiation and 
during the conduct of the trial. This decision 
was in keeping with the pragmatic nature of the 
trial. The treatment protocol in this trial was 
also similar to the treatment protocol that was 
used in a trial of hypothermia for intracranial 
hypertension after TBI.18 The numbers of patients 
who received the optional stage 1 and stage 2 
interventions were similar in the two groups, a 
finding that suggests that concomitant interven-
tions were not responsible for the observed result.
In contrast to the present trial, the DECRA 
trial9 showed that patients undergoing craniecto-
my had worse ratings on the GOS-E at 6 months 
than those receiving standard care (P = 0.03), al-
though the rates of death were similar at 6 months 
(19% and 18%, respectively). The DECRA trial 
aimed to assess the effectiveness of early crani-
ectomy — offered as a stage 2 treatment within 
72 hours after injury — for moderate intracranial 
hypertension (intracranial pressure, >20 mm Hg 
for 15 minutes within a 1-hour period [continu-
ous or cumulative]) in patients with diffuse TBI.9 
The RESCUEicp trial aimed to assess the effec-
tiveness of decompressive craniectomy offered as 
a last-tier treatment.11 In addition, patients with 
intracranial hematoma (evacuated or nonevacu-
ated) were excluded from the DECRA trial, 
whereas they represented almost 20% of the 
patients in the RESCUEicp trial. Moreover, uni-
lateral decompressive craniectomy (hemicraniec-
tomy) was not allowed by the protocol of the 
DECRA trial, whereas it was an option in the 
protocol of the RESCUEicp trial.
Our trial provides quantitative evidence to in-
form the debate around historical concerns that 
decompressive craniectomy simply increases the 
number of patients who survive in a vegetative 
state.8 The survival advantage of decompressive 
craniectomy in this trial was translated to both 
dependent and independent living. Clinicians and 
family members will need to be aware of this 
issue when making decisions regarding treat-
ment options. Improved control of intracranial 
pressure with surgery may have accounted for 
mortality that was lower than that observed with 
medical management, but our trial did not test 
this hypothesis.4
Some limitations of the present trial should 
be noted. First, the clinical teams who cared for 
the patients were aware of trial-group assign-
ments. However, outcome adjudication on the 
basis of the GOS-E questionnaires was done at 
the coordinating center by personnel who were 
unaware of the group assignments. Second, a 
relatively large proportion of patients in the 
medical group underwent decompressive crani-
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ectomy; this situation may have diluted the ob-
served treatment effect. Third, 10 patients were 
excluded from all analyses owing to withdrawal 
of consent or to a lack of valid consent, and 
7 more patients in the medical group were lost 
to primary follow-up. Fourth, long-term data on 
cranial reconstruction — a procedure that is 
usually necessary a few weeks to months after 
decompressive craniectomy — were not system-
atically obtained owing to the pragmatic nature 
of the trial. This important aspect of treatment 
needs to be explored in future studies. Finally, 
the present trial did not examine the effective-
ness of primary decompressive craniectomy, 
which is undertaken more frequently than sec-
ondary decompressive craniectomy.19,20
In conclusion, at 6 months, decompressive 
craniectomy for severe and refractory intracranial 
hypertension after TBI resulted in mortality that 
was 22 percentage points lower than that with 
medical management. Surgery also was associ-
ated with higher rates of vegetative state, lower 
severe disability, and upper severe disability than 
medical management. The rates of moderate 
disability and good recovery with surgery were 
similar to those with medical management.
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